VOLTAIRE-X: Pharmacokinetics, Safety, Immunogenicity and Efficacy of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: a Randomized, Double-blind, Parallel-arm, Multiple-dose, Active Comparator Trial
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics; Registrational
- Acronyms VOLTAIRE-X
- Sponsors Boehringer Ingelheim
- 10 Oct 2019 Status changed from recruiting to completed.
- 05 Sep 2019 This trial has been completed in Hungary
- 21 Jun 2019 This trial has been completed in Latvia.